F. Gómez - Concepedia

Author

F. Gómez

Also Known As

Anna Degracia, Anna Parera Pous, Anna Salazar Degracia, Clara Vilà-Vilardel, F Gomez, F Gómez, F. Gomez, F. Gómez, F. Olive, F. Parrilla

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Centre Léon Bérard Institut Gustave Roussy St. Michael's Hospital Imperial College London Radboud University Medical Center

About

F. Gómez is an author at Centre Léon Bérard specializing in medicine, social sciences, and outcomes research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	233
2	Social Sciences	2	2	45
3	Public Health	1	1	34
4	Epidemiology	1	1	34
5	Health Informatics	1	1	34

F. Gómez

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Phase III Randomized Trial of <i>Calendula Officinalis</i> Compared With Trolamine for the Prevention of Acute Dermatitis During Irradiation for Breast Cancer P. Pommier, F. Gómez, Marie Pierre Sunyach, Journal of Clinical Oncology	2004	364
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. Cesare Guglielmi, F. Gómez, Thierry Philip, Journal of Clinical Oncology	1998	156
Impact of targeting deviations on outcome in medulloblastoma: study of the French society of pediatric oncology (SFOP)11Participating institutions including more than one patient: Centre Paul Papin—Angers (M. Mege); Bruxelles (C. De Vriendt); Centre Claudius Regaud—Toulouse (F. Soum); Hôpital Charles Nicolle—Rouen (S. Seng); Institut Jean Godinot—Reims (X. Panis); Hôpital Bellevue—Saint-Etienne (T. Schmitt). C. Carrié, S. Hoffstetter, F. Gómez, International Journal of Radiation OncologyBiologyPhysics Neuro-oncologyPediatric Brain TumorsPediatric NeurosurgeryMedicineCancer Management	1999	154
Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19 Simin Florescu, Delia Stanciu, Mihaela Zaharia, JAMA	2022	147
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial Simin Florescu, Delia Stanciu, Mihaela Zaharia, JAMA	2022	133
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie. Alain Ravaud, B. Audhuy, F. Gómez, Journal of Clinical Oncology	1998	81
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France Jean‐Yves Blay, Sophie Boucher, Béatrice Le Vu, ESMO Open	2021	75
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19 Simin Aysel Florescu, Mihaela Zaharia, Alma Kosa, JAMA	2023	66
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial Jean‐Pierre Lotz, B. Bui, F. Gómez, Annals of Oncology	2005	56
Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation Didier Frappaz, A. Bonneu, P. Chauvot, Medical and Pediatric Oncology	2000	40

Page 1